FGFR2 gene amplification and clinicopathological features in gastric cancer

British Journal of Cancer

Volumn 106, Issue 4, 2012, Pages 727-732

  Matsumoto, K ^a   Arao, T ^a   Hamaguchi, T ^b   Shimada, Y ^b   Kato, K ^b   Oda, I ^b   Taniguchi, H ^b   Koizumi, F ^b   Yanagihara, K ^c   Sasaki, H ^d   Nishio, K ^a   Yamada, Y ^b  

^a KINKI UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c YASUDA WOMEN'S UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

FGFR2; gastric cancer; gene amplification

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; DRUG SENSITIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; STOMACH NEOPLASMS;

EID: 84856829698     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.603     Document Type: Article

References (28)

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697
2. Beenken A, Mohammadi M (2009) The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 8(3): 235-253
3. Bittoni A, Maccaroni E, Scartozzi M, Berardi R, Cascinu S (2010) Chemotherapy for locally advanced and metastatic gastric cancer: State of the art and future perspectives. Eur Rev Med Pharmacol Sci 14(4): 309-314
4. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet 23: 18-20 (Pubitemid 29418781)
5. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C (1997) Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups. Cancer Res 57: 4360-4367 (Pubitemid 27413447)
6. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105: 8713-8717 (Pubitemid 351987745)
7. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: Mechanisms of antitumour activity. Nat Rev Cancer 8(8): 579-591
8. Fujii M, Kochi M, Takayama T (2010) Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today 40(4): 295-300
9. Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071 (Pubitemid 29233220)
10. Grose R, Dickson C (2005) Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16: 179-186 (Pubitemid 40616115)
11. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T, Terada M (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2: 1373-1381 (Pubitemid 26299437)
12. Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H, Katoh O, Yoshida T, Sugimura T, Terada M (1990) K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA 87: 5983-5987
13. Itoh H, Hattori Y, Sakamoto H, Ishii H, Kishi T, Sasaki H, Yoshida T, Koono M, Sugimura T, Terada M (1994) Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Res 54: 3237-3241 (Pubitemid 24208935)
14. Jang JH, Shin KH, Park JG (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61: 3541-3543
15. Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K, Nishio K (2010) FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res 70(5): 2053-2063
16. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Yamada Y, Arao T, Nishio K, Michalowski A, Green JE (2010) Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J; e-pub ahead of print 21 December 2010
17. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K (2009) mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69(18): 7160-7164
18. Moffa AB, Tannheimer SL, Ethier SP (2004) Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2: 643-652 (Pubitemid 39557667)
19. Motoi T, Kumagai A, Tsuji K, Imamura T, Fukusato T (2010) Diagnostic utility of dual-color break-apart chromogenic in situ hybridization for the detection of rearranged SS18 in formalin-fixed, paraffin-embedded synovial sarcoma. Hum Pathol 41(10): 1397-1404
20. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K (2006) A novel molecular targeting compound as K-samII/ FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131(5): 1530-1541 (Pubitemid 44708935)
21. Peng DF, Sugihara H, Mukaisho K, Tsubosa Y, Hattori T (2003) Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: Metaphase-and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. J Pathol 201(3): 439-450 (Pubitemid 37408265)
22. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C, Murphy KM, Tsiamouri A, Beeson K, Simpson AJ, Venter JC, Riggins GJ, Strausberg RL (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA 102: 14344-14349 (Pubitemid 41429700)
23. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N, Nishio K (2007) AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 13(10): 3051-3057 (Pubitemid 46849582)
24. Toyokawa T, Yashiro M, Hirakawa K (2009) Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep 21(4): 875-880
25. Tsujimoto H, Sugihara H, Hagiwara A, Hattori T (1997) Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 431(6): 383-389 (Pubitemid 27519371)
26. Turner N, Grose R (2010) Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10(2): 116-129
27. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70(5): 2085-2094
28. Ueda T, Sasaki H, Kuwahara Y, Nezu M, Shibuya T, Sakamoto H, Ishii H, Yanagihara K, Mafune K, Makuuchi M, Terada M (1999) Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res 59(24): 6080-6086 (Pubitemid 30035624)